O'Farrell Elizabeth G. 4

What Happened
Elizabeth O'Farrell, an Outside Director of SpyGlass Pharma, was granted 13,700 shares (reported as a derivative award) on February 5, 2026. The award shows a $0.00 acquisition price (no cash paid) and is recorded as an issuance of equity under the company's plan rather than an open-market purchase or sale.

Key Details

• Transaction date: February 5, 2026 — Grant/award of 13,700 shares at $0.00 (derivative).
• Filing date: Form 4 filed February 9, 2026 — appears to be within the typical two-business-day filing window.
• Shares owned after transaction: not specified in the filing.
• Vesting note (footnote): 100% of the shares vest on the earlier of (i) the one-year anniversary of the Feb 5, 2026 grant or (ii) the day before the issuer's next annual meeting, provided the reporting person continues as an Outside Director.
• No indication of tax withholding, 10b5-1 plan, cashless exercise, or sale of shares in this filing.

Context
This was a compensatory equity grant to a director (common for board compensation). These awards are typically subject to vesting and do not represent an immediate cash investment or sale by the insider. Because it's a grant (not a purchase or sale), it should be viewed as routine director compensation rather than a direct bullish or bearish market signal.